Plasma Pro-B-Type Natriuretic Peptide Testing as a Screening Method for Hypertrophic Cardiomyopathy
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | FERNANDES, Fabio | |
dc.contributor.author | ARTEAGA-FERNANDEZ, Edmundo | |
dc.contributor.author | ANTUNES, Murillo de Oliveira | |
dc.contributor.author | BUCK, Paula | |
dc.contributor.author | MARSIGLIA, Julia Daher Carneiro | |
dc.contributor.author | MATSUMOTO, Afonso | |
dc.contributor.author | NASTARI, Luciano | |
dc.contributor.author | KRIEGER, Jose Eduardo | |
dc.contributor.author | PEREIRA, Alexandre Costa | |
dc.contributor.author | MADY, Charles | |
dc.date.accessioned | 2013-10-02T19:19:12Z | |
dc.date.available | 2013-10-02T19:19:12Z | |
dc.date.issued | 2012 | |
dc.description.abstract | Background: Clinical multistage risk assessment associated with electrocardiogram (ECG) and NT-proBNP may be a feasible strategy to screen hypertrophic cardiomyopathy (HCM). We investigated the effectiveness of a screening based on ECG and NT-proBNP in first-degree relatives of patients with HCM. Methods and Results: A total of 106 first-degree relatives were included. All individuals were evaluated by echocardiography, ECG, NT-proBNP, and molecular screening (available for 65 individuals). From the 106 individuals, 36 (34%) had diagnosis confirmed by echocardiography. Using echocardiography as the gold standard, ECG criteria had a sensitivity of 0.71, 0.42, and 0.52 for the Romhilt-Estes, Sokolow-Lyon, and Cornell criteria, respectively. Mean values of NT-ProBNP were higher in affected as compared with nonaffected relatives (26.1 vs. 1290.5, P < .001). The AUC of NT-proBNP was 0.98. Using a cutoff value of 70 pg/mL, we observed a sensitivity of 0.92 and specificity of 0.96. Using molecular genetics as the gold standard, ECG criteria had a sensitivity of 0.67, 0.37, and 0.42 for the Romhilt-Estes, Sokolow-Lyon, and Cornell criteria, respectively. Using a cutoff value of 70 pg/mL, we observed a sensitivity of 0.83 and specificity of 0.98. Conclusion: Values of NT-proBNP above 70 pg/mL can be used to effectively select high-risk first-degree relatives for HCM screening. (J Cardiac Fail 2012;18:564-568) | |
dc.description.index | MEDLINE | |
dc.identifier.citation | JOURNAL OF CARDIAC FAILURE, v.18, n.7, p.564-568, 2012 | |
dc.identifier.doi | 10.1016/j.cardfail.2012.04.005 | |
dc.identifier.issn | 1071-9164 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/2502 | |
dc.language.iso | eng | |
dc.publisher | CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS | |
dc.relation.ispartof | Journal of Cardiac Failure | |
dc.rights | restrictedAccess | |
dc.rights.holder | Copyright CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS | |
dc.subject | Hypertrophic cardiomyopathy | |
dc.subject | NT-proBNP | |
dc.subject | familial screening | |
dc.subject.other | left-ventricular hypertrophy | |
dc.subject.other | diastolic dysfunction | |
dc.subject.other | in-vitro | |
dc.subject.other | genotype | |
dc.subject.other | point | |
dc.subject.other | age | |
dc.subject.wos | Cardiac & Cardiovascular Systems | |
dc.title | Plasma Pro-B-Type Natriuretic Peptide Testing as a Screening Method for Hypertrophic Cardiomyopathy | |
dc.type | article | |
dc.type.category | original article | |
dc.type.version | publishedVersion | |
dspace.entity.type | Publication | |
hcfmusp.citation.scopus | 6 | |
hcfmusp.contributor.author-fmusphc | FERNANDES, Fabio | |
hcfmusp.contributor.author-fmusphc | ARTEAGA-FERNANDEZ, Edmundo | |
hcfmusp.contributor.author-fmusphc | ANTUNES, Murillo de Oliveira | |
hcfmusp.contributor.author-fmusphc | BUCK, Paula | |
hcfmusp.contributor.author-fmusphc | MARSIGLIA, Julia Daher Carneiro | |
hcfmusp.contributor.author-fmusphc | MATSUMOTO, Afonso | |
hcfmusp.contributor.author-fmusphc | NASTARI, Luciano | |
hcfmusp.contributor.author-fmusphc | KRIEGER, Jose Eduardo | |
hcfmusp.contributor.author-fmusphc | PEREIRA, Alexandre Costa | |
hcfmusp.contributor.author-fmusphc | MADY, Charles | |
hcfmusp.description.beginpage | 564 | |
hcfmusp.description.endpage | 568 | |
hcfmusp.description.issue | 7 | |
hcfmusp.description.volume | 18 | |
hcfmusp.jcr | J CARD FAIL | |
hcfmusp.lim.ref | 2012 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.pubmed | 22748490 | |
hcfmusp.origem.scopus | 2-s2.0-84863008691 | |
hcfmusp.origem.wos | WOS:000306386700007 | |
hcfmusp.publisher.city | PHILADELPHIA | |
hcfmusp.publisher.country | USA | |
hcfmusp.relation.reference | Ala-Kopsala M, 2010, CLIN CHEM, V56, P1822, DOI 10.1373/clinchem.2010.148775 | |
hcfmusp.relation.reference | Arteaga E, 2005, AM HEART J, V149, P1099, DOI 10.1016/j.ahj.2004.09.049 | |
hcfmusp.relation.reference | Arteaga E, 2005, AM HEART J, V150, P1228, DOI 10.1016/j.ahj.2005.02.045 | |
hcfmusp.relation.reference | Downie PF, 1999, CLIN SCI, V97, P255, DOI 10.1042/CS19990084 | |
hcfmusp.relation.reference | Fox PR, 2011, J VET INTERN MED, V25, P1010, DOI 10.1111/j.1939-1676.2011.00776.x | |
hcfmusp.relation.reference | Hildebrandt P, 2010, EUR HEART J, V31, P1881, DOI 10.1093/eurheartj/ehq163 | |
hcfmusp.relation.reference | Ho CY, 2010, CIRCULATION, V122, P2430, DOI 10.1161/CIRCULATIONAHA.110.978924 | |
hcfmusp.relation.reference | Ho CY, 2006, CIRCULATION, V113, pE396, DOI 10.1161/CIRCULATIONAHA.105.579268 | |
hcfmusp.relation.reference | Ho CY, 2009, CIRC-CARDIOVASC GENE, V2, P314, DOI 10.1161/CIRCGENETICS.109.862128 | |
hcfmusp.relation.reference | Ho CY, 2002, CIRCULATION, V105, P2992, DOI 10.1161/01.CIR.0000019070.70491.6D | |
hcfmusp.relation.reference | Ho CY, 2010, CIRCULATION, V122, P2440 | |
hcfmusp.relation.reference | Kaski JP, 2008, HEART, V94, P1307, DOI 10.1136/hrt.2007.126748 | |
hcfmusp.relation.reference | Konno T, 2010, CURR OPIN CARDIOL, V20, P205 | |
hcfmusp.relation.reference | Pagourelias ED, 2010, INT J CLIN PRACT, V64, P511, DOI 10.1111/j.1742-1241.2009.02184.x | |
hcfmusp.relation.reference | Pieroni M, 2007, J CARD FAIL, V13, P380, DOI 10.1016/j.cardfail.2007.01.011 | |
hcfmusp.relation.reference | Rakowski H, 1996, J Am Soc Echocardiogr, V9, P736, DOI 10.1016/S0894-7317(96)90076-0 | |
hcfmusp.relation.reference | Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4 | |
hcfmusp.relation.reference | Rodrigues SL, 2008, ARQ BRAS CARDIOL, V90, P46, DOI 10.1590/S0066-782X2008000100008 | |
hcfmusp.relation.reference | ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5 | |
hcfmusp.relation.reference | SAVAGE DD, 1978, CIRCULATION, V58, P402 | |
hcfmusp.relation.reference | SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1 | |
hcfmusp.relation.reference | Tschope C, 2005, EUR HEART J, V26, P2277, DOI 10.1093/eurheartj/ehi406 | |
hcfmusp.relation.reference | Yamada H, 2002, J AM SOC ECHOCARDIOG, V15, P1238, DOI 10.1067/mje.2002.12877 | |
hcfmusp.scopus.lastupdate | 2024-10-12 | |
hcfmusp.sjr | 23826 | |
relation.isAuthorOfPublication | 955a013c-ecfc-44c1-94f2-972929ebdcfd | |
relation.isAuthorOfPublication | 9fc8d70f-9a22-4326-ba13-db0346392674 | |
relation.isAuthorOfPublication | 6d8b1a9f-d8c3-4054-b5a6-a7482f032c6f | |
relation.isAuthorOfPublication | 1422690b-e719-46f2-a9f1-c15f1cf1eba1 | |
relation.isAuthorOfPublication | 8fcc68cf-3928-4c9f-ae71-75a55a4cbd33 | |
relation.isAuthorOfPublication | 9d67a2f7-e589-4fbc-87b0-189fa7dbe111 | |
relation.isAuthorOfPublication | 48cc5b07-b2f8-4c74-b17b-142ed8fe4174 | |
relation.isAuthorOfPublication | a970d450-bcd4-4662-94d6-ad1c6d043b3c | |
relation.isAuthorOfPublication | 415ce7ca-65c1-4699-b6f4-19dae8b03849 | |
relation.isAuthorOfPublication | ed3e630e-476e-42c6-bfc6-3c89a5f4eb67 | |
relation.isAuthorOfPublication.latestForDiscovery | 955a013c-ecfc-44c1-94f2-972929ebdcfd |
Arquivos
Pacote Original
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- art_FERNANDES_Plasma_Pro_B_Type_Natriuretic_Peptide_Testing_as_2012.PDF
- Tamanho:
- 141.28 KB
- Formato:
- Adobe Portable Document Format
- Descrição:
- publishedVersion (English)